Longboard Pharmaceuticals, Inc.
DelistedCIK 1832168fmd_0S6Q4VDX50JJ1QV21NYKEZ8ZWXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 03, 2020 to Sep 30, 2024, 19 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|
| Research and development | 5 | 20 | 35 | 44 |
| Total operating expenses | 14 | 28 | 45 | 57 |
| Operating income | (14) | (28) | (45) | (57) |
| Income tax expense | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (14) | (28) | (44) | (54) |
| Net income | (14) | (28) | (44) | (54) |